Literature DB >> 24300434

Polyunsaturated fatty acid associations with dopaminergic indices in major depressive disorder.

M Elizabeth Sublette1, Hanga C Galfalvy1, Joseph R Hibbeln2, John G Keilp1, Kevin M Malone3, Maria A Oquendo1, J John Mann1.   

Abstract

Dopaminergic function is thought to be altered in major depression and, in animal studies, is reduced in omega-3 polyunsaturated fatty acid (PUFA) deficiency states. Therefore we studied PUFAs and resting prolactin, a marker for dopaminergic tone, and cerebrospinal fluid homovanillic acid (HVA), the chief dopamine metabolite. In medication-free adults (n = 23) with DSM-IV major depressive disorder (MDD), we measured plasma phospholipid levels of omega-3 PUFAs docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), the omega-6 PUFA arachidonic acid (AA), and plasma prolactin levels before and after administration of dl-fenfluramine (FEN). In a subset of patients (n = 14), cerebrospinal fluid levels of HVA and the serotonin metabolite, 5-hydroxyindoleacetic acid (5-HIAA), were obtained through lumbar puncture. Baseline prolactin was negatively correlated with omega-3 PUFAs (logDHA, F(1,21) = 20.380, p < 0.001; logEPA, F(1,21) = 10.051, p = 0.005) and positively correlated with logAA:DHA (F(1,21) = 15.263, p = 0.001), a measure of omega-6/omega-3 balance. LogDHA was negatively correlated with CSF HVA (Spearman's ρ = -0.675, p = 0.008) but not 5-HIAA (Spearman's ρ = -0.143, p = 0.626) after controlling for sex and HVA - 5-HIAA correlation. PUFAs did not predict the magnitude of the FEN-stimulated change in prolactin, considered to be a serotonin effect. The robust relationship of omega-3 PUFAs with dopaminergic but not serotonergic indices suggests that omega-6:omega-3 balance may impact depression pathophysiology through effects on the dopaminergic system.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24300434      PMCID: PMC3956108          DOI: 10.1017/S1461145713001399

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  77 in total

1.  A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression.

Authors:  Pao-Yen Lin; Shih-Yi Huang; Kuan-Pin Su
Journal:  Biol Psychiatry       Date:  2010-05-10       Impact factor: 13.382

Review 2.  The role of dopamine in the pathophysiology of depression.

Authors:  Boadie W Dunlop; Charles B Nemeroff
Journal:  Arch Gen Psychiatry       Date:  2007-03

3.  Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression.

Authors:  M Elizabeth Sublette; Steven P Ellis; Amy L Geant; J John Mann
Journal:  J Clin Psychiatry       Date:  2011-09-06       Impact factor: 4.384

Review 4.  EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials.

Authors:  Julian G Martins
Journal:  J Am Coll Nutr       Date:  2009-10       Impact factor: 3.169

5.  Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder.

Authors:  Lev Gertsik; Russell E Poland; Catherine Bresee; Mark Hyman Rapaport
Journal:  J Clin Psychopharmacol       Date:  2012-02       Impact factor: 3.153

6.  Selective enhancement of mesocortical dopaminergic transmission by noradrenergic drugs: therapeutic opportunities in schizophrenia.

Authors:  Mercè Masana; Analía Bortolozzi; Francesc Artigas
Journal:  Int J Neuropsychopharmacol       Date:  2010-08-12       Impact factor: 5.176

7.  Chronic fluoxetine increases cytosolic phospholipase A(2) activity and arachidonic acid turnover in brain phospholipids of the unanesthetized rat.

Authors:  Ho-Joo Lee; Jagadeesh S Rao; Renee N Ertley; Lisa Chang; Stanley I Rapoport; Richard P Bazinet
Journal:  Psychopharmacology (Berl)       Date:  2006-11-09       Impact factor: 4.530

8.  Membrane raft organization is more sensitive to disruption by (n-3) PUFA than nonraft organization in EL4 and B cells.

Authors:  Benjamin Drew Rockett; Andrew Franklin; Mitchel Harris; Heather Teague; Alexis Rockett; Saame Raza Shaikh
Journal:  J Nutr       Date:  2011-04-27       Impact factor: 4.798

9.  Chronic imipramine but not bupropion increases arachidonic acid signaling in rat brain: is this related to 'switching' in bipolar disorder?

Authors:  H-J Lee; J S Rao; L Chang; S I Rapoport; H-W Kim
Journal:  Mol Psychiatry       Date:  2008-11-04       Impact factor: 15.992

Review 10.  Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid?

Authors:  Brian M Ross; Jennifer Seguin; Lee E Sieswerda
Journal:  Lipids Health Dis       Date:  2007-09-18       Impact factor: 3.876

View more
  19 in total

Review 1.  The Deleterious Effects of Oxidative and Nitrosative Stress on Palmitoylation, Membrane Lipid Rafts and Lipid-Based Cellular Signalling: New Drug Targets in Neuroimmune Disorders.

Authors:  Gerwyn Morris; Ken Walder; Basant K Puri; Michael Berk; Michael Maes
Journal:  Mol Neurobiol       Date:  2015-08-27       Impact factor: 5.590

2.  Brain serotonin transporter binding, plasma arachidonic acid and depression severity: A positron emission tomography study of major depression.

Authors:  Manesh Gopaldas; Francesca Zanderigo; Serena Zhan; R Todd Ogden; Jeffrey M Miller; Harry Rubin-Falcone; Thomas B Cooper; Maria A Oquendo; Gregory Sullivan; J John Mann; M Elizabeth Sublette
Journal:  J Affect Disord       Date:  2019-07-05       Impact factor: 4.839

Review 3.  Pathways of polyunsaturated fatty acid utilization: implications for brain function in neuropsychiatric health and disease.

Authors:  Joanne J Liu; Pnina Green; J John Mann; Stanley I Rapoport; M Elizabeth Sublette
Journal:  Brain Res       Date:  2014-12-08       Impact factor: 3.252

4.  Low plasma eicosapentaenoic acid levels are associated with elevated trait aggression and impulsivity in major depressive disorder with a history of comorbid substance use disorder.

Authors:  Anne Mette Beier; Lotte Lauritzen; Hanga C Galfalvy; Thomas B Cooper; Maria A Oquendo; Michael F Grunebaum; J John Mann; M Elizabeth Sublette
Journal:  J Psychiatr Res       Date:  2014-06-26       Impact factor: 4.791

5.  Alterations in levels and ratios of n-3 and n-6 polyunsaturated fatty acids in the temporal cortex and liver of vervet monkeys from birth to early adulthood.

Authors:  Leslie R Miller; Matthew J Jorgensen; Jay R Kaplan; Michael C Seeds; Elaheh Rahbar; Timothy M Morgan; Andrea Welborn; Sarah M Chilton; Julianne Gillis; Austin Hester; Mae Rukstalis; Susan Sergeant; Floyd H Chilton
Journal:  Physiol Behav       Date:  2015-12-17

6.  Omega-3 Fatty Acids and Cholesterol Have a Main Role in Antidepression Diet of Iranian Traditional Medicine.

Authors:  Mohammad Mahdi Ahmadian-Attari; Ahmad Ali Noorbala; Alireza Khoshdel; Mohammad Kamalinejad; Arsia Taghva
Journal:  J Evid Based Complementary Altern Med       Date:  2016-07-07

Review 7.  Acyl-CoA synthetases as regulators of brain phospholipid acyl-chain diversity.

Authors:  Regina F Fernandez; Jessica M Ellis
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2020-09-15       Impact factor: 4.006

8.  N-3 polyunsaturated fatty acids promote astrocyte differentiation and neurotrophin production independent of cAMP in patient-derived neural stem cells.

Authors:  Jiang-Zhou Yu; Jennifer Wang; Steven D Sheridan; Roy H Perlis; Mark M Rasenick
Journal:  Mol Psychiatry       Date:  2020-06-05       Impact factor: 15.992

9.  Targeted alterations in dietary n-3 and n-6 fatty acids improve life functioning and reduce psychological distress among patients with chronic headache: a secondary analysis of a randomized trial.

Authors:  Christopher E Ramsden; Keturah R Faurot; Daisy Zamora; Olafur S Palsson; Beth A MacIntosh; Susan Gaylord; Ameer Y Taha; Stanley I Rapoport; Joseph R Hibbeln; John M Davis; J Douglas Mann
Journal:  Pain       Date:  2015-04       Impact factor: 7.926

Review 10.  Shared Biological Pathways between Antipsychotics and Omega-3 Fatty Acids: A Key Feature for Schizophrenia Preventive Treatment?

Authors:  Ariel Frajerman; Linda Scoriels; Oussama Kebir; Boris Chaumette
Journal:  Int J Mol Sci       Date:  2021-06-26       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.